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Understanding heterogeneity in adaptive immune responses is essential to dissect pathways of memory B
and T cell differentiation and to define correlates of protective immunity. Traditionally, immunologists have
deconvoluted this heterogeneity with flow cytometry—with combinations of markers to define signatures
that represent specific lineages, differentiation states, and functions. Genome-scale technologies have
become widely available and provide the ability to define expression signatures—sets of genes—that repre-
sent discrete biological properties of cell populations. Because genomic signatures can serve as surrogates
of a phenotype, function, or cell state, they can integrate phenotypic information between experiments, cell
types, and species. Here, we discuss how integration of well-defined expression signatures across experi-
mental conditions together with functional analysis of their component genes could provide new opportuni-
ties to dissect the complexity of the adaptive immune response and map the immune response to vaccines
and pathogens.Introduction
Understanding and manipulating the host immune response to
pathogens is a central goal in immunology and is critical to ratio-
nally designing effective vaccines. The fundamental pathways
that control the development of robust and protective immuno-
logic responses, however, remain incompletely understood.
This challenge is illustrated by our inability to generate broadly
protective vaccines against HIV, hepatitis C virus (HCV), influ-
enza virus, malaria, and mycobacterium tuberculosis. These fail-
ures highlight the fact that as yet, we do not understand the
mechanisms that form and sustain highly protective memory B
and T cells in many settings. Moreover, in most instances, we
lack accurate surrogates of this process to help guide vaccine
development.
One of the principal challenges to defining the regulation of the
memory lymphocyte response is the complexity of the system
itself. The memory lymphocyte compartment encompasses
dozens of phenotypically and functionally distinct cell types
and probably a large number of phenotypes beyond those that
are already characterized (Kaech and Wherry, 2007; Sallusto
et al., 2004). In addition, each memory B or T cell subpopulation
can express a complex array of surface molecules that interact
with the surrounding environment, providing a dynamic sensory
apparatus that registers subtle alterations in soluble and
membrane-bound ligands. Each of these interactions, singly or
in combination, has the capacity to set in motion a range of
cellular responses: transient effects such as cytokine secretion
or migration; or dramatic, sometimes irreversible changes,
such as differentiation or lineage commitment. Thus the chal-
lenge of understanding the complexity of the adaptive immune
response to pathogens lies in mapping the range of cellular
phenotypes, lineages, or differentiation states that exist, the rela-
tionships that define them, and the signals that modulate them.
The early adoption of flow cytometry as an integral tool in
immunology led to the discovery of the fundamental cell pheno-152 Immunity 32, February 26, 2010 ª2010 Elsevier Inc.types that are involved in innate and adaptive immune responses
(Chattopadhyay et al., 2008). Combinations of surface and
intracellular markers now are used to identify a large number of
operationally distinct subpopulations of lymphocytes. Immunol-
ogists, for instance, equate cells that stain with themarkers CD4,
CD25, and Foxp3 with (at least in most cases) regulatory T cells
(Zheng and Rudensky, 2007). For many cell states in the immune
system, a combination of markers can provide a sufficiently
distinctive pattern to serve as surrogate for the phenotype itself.
However, it is likely that important biological distinctions exist
within apparently homogeneous cell populations, but have yet
to be identified because of the lack of systematic and unbiased
approaches for recognizing such subclasses.
Over the last 20 years, techniques to conduct large-scale,
highly parallel surveys of gene expression, genetic polymor-
phisms, and protein abundance have become feasible, acces-
sible, and widely used. Immunologists can now profile popula-
tions of cells in the immune system not only by multiparameter
flow cytometry, but with genome-wide profiles of gene expres-
sion (Heng et al., 2008; Hyatt et al., 2006), microRNA expression
(Schones et al., 2008; Wu et al., 2007), and histone modification
(Araki et al., 2009; Schones et al., 2008). The introduction of tools
to acquire massively complex signatures from discrete popula-
tions of lymphocytes has fundamentally altered the lens through
which immunologists now study adaptive immunity.
This perspective will focus on the concept that genome-wide
transcriptional profiles—gene expression signatures—can serve
as surrogates for biological phenotypes of cell populations within
the immune system (Nevins and Potti, 2007). This concept is
important for two reasons. First, the complexity afforded by mi-
croarray analysis of 20,000 genes allows subtle but important
distinctions in the biological condition to be determined. The
second reason is that gene expression signatures can serve to
translate a phenotype from one experimental situation to
another. A gene expression signature that defines a cell state
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all genes or,more usefully, theminimal subset of genes that suffi-
ciently defines the biological phenotype of interest. Because
signatures can act as surrogates for the biology they represent,
they allow the presence of an interesting phenotype to be
studied in a variety of contexts. A signature as a representation
of a cell type, differentiation state, or biological process allows
it to serve as an intermediary between different experiments.
Moreover, the signature itself provides an enriched pool of genes
whose function may be integral to the phenotype under study.
In the sections below, we discuss the fundamental shift in
analyzing complex genomic data (e.g., microarray data, etc.) in
a gene-by-gene, knowledge-driven manner to analyses that
consider complex patterns of gene expression in toto. We will
also highlight some of the computational approaches that have
been developed to extract biological meaning from sets of genes
rather than individual genes. The use of gene expression signa-
tures as analytic entities has enabled new and more complex
types of genome-wide experimental approaches. The ability to
integrate different, large-scale, sometimes orthogonal experi-
mental approaches and then to extract meaning from the huge
amounts of data generated, in many cases, depends fundamen-
tally on the ability to define and use gene expression signatures.
Finally, the ability to use genomic approaches as ‘‘active’’ exper-
imental tools by functionally annotating all genes in a gene set,
microarray-defined signature, or the whole genome is dis-
cussed. The potential application of such approaches for dis-
secting the mechanisms of immunological memory and for
probing the effectiveness of different vaccines or other immuno-
logical interventions is highlighted.
Initial Applications of Gene Expression Profiling
in Immunology
So far, the search for phenotypic markers (genes) or functional
characteristics that define the phenotypes of cells in the adaptive
immune system has been driven by the rational selection of
known, biologically relevant characteristics. CCR7 and CD62L,
for instance, are used to demarcate naive and central memory
T cells because these surface receptors are known to guide
these T cells to the lymph node (Sallusto et al., 1999; Weninger
et al., 2001). In other words, the selection of candidate genes
or functional characteristics that could define a phenotypically
distinct population of cells is essentially knowledge driven.
However, a central disadvantage of the knowledge-driven
approach is that the result will be only as good as the body of
knowledge: genes that are not known to be involved in the
phenotype cannot be considered.
An alternative to knowledge-based identification of immune
correlates is therefore a data-driven approach, in which
genome-wide analyses of gene expression are carried out, and
then correlates between patterns of gene expression and the
phenotype of interest are sought. This approach is unbiased
because there are no assumptions about which genes are likely
to be involved in the process of interest. In addition, this
approach opens the door to biologic discovery because genes
and pathways not previously known to be involved in the immune
response can be identified in the process.
High-densitymicroarrayswere introduced in themid-1990s by
Patrick Brown and colleagues at Stanford University (Schenaet al., 1995). These approaches were soon applied to immuno-
logical questions, and around the turn of the century several
key studies were published demonstrating the power of this
approach for immunology. Some of the earliest sets of data for
B and T cells with microarrays examined activation-induced
changes in gene expression (Alizadeh et al., 1998; Teague
et al., 1999). These early studies confirmed previous work on
lymphocyte activation that identified cell cycle regulation, induc-
tion of chemokines, and the ordered changes in gene expression
after activation as key events upon T or B cell stimulation and
helped define the genes associated with lymphocyte activation.
These observations were a crucial early validation of microarrays
for global investigation of gene expression in the immune system
and its application to biologic discovery.
Some of the first genomic studies addressing questions about
immunological memory focused on the transcriptional changes
in B cells associated with the germinal center fate decisions
and on the progressive acquisition of memory qualities in CD8+
T cells (Kaech et al., 2002; Shaffer et al., 2000, 2001, 2002).
For B cells, events in the germinal center determine the fate deci-
sions for activated B cells becoming either self-renewing
memory B cells or terminally differentiated but long-lived plasma
cells. In seminal studies, Staudt and colleagues, for example,
used microarrays to identify the role of Blimp-1-mediated
repression of memory B cell development and promotion of
the plasma cell fate (Shaffer et al., 2002). These studies revealed
a clear role of Blimp-1 as a transcriptional repressor of a broad
program of B cell memory but also pointed to a smaller set of
genes that were upregulated in the presence of Blimp-1
including the key transcriptional regulator Xbp-1.
Around the same time, the molecular profiles of memory CD8+
T cells were also defined via microarrays by Kaech and
colleagues (Kaech et al., 2002) who analyzed the time course
of gene expression as well as functional development of memory
CD8+ T cells responding to LCMV infection. Comparison of
memory CD8+ T cells obtained at day 30 after infection with
effector CD8 T cells from day 8 after infection or with naive
T cells via supervised analysis demonstrated large numbers of
differentially expressed genes. The breadth of these transcrip-
tional changes had several implications. First, the number of
genes differentially expressed between effectors and memory
CD8+ T cells strongly suggested that memory CD8+ T cells
were not simply ‘‘resting effectors’’ but rather were a distinct
state of differentiation. Second, the time course of the changes
suggested that the development of memory lymphocytes
was a gradual process that continued long after viral infection
was cleared. Third, the scope of the observed changes indi-
cated that the differentiation of memory lymphocytes must
require complex but coordinate regulation of a broad transcrip-
tional program.
As the ability to generate genome-wide expression profiles
became more broadly adopted, a large number of studies
focused on key molecules and pathways involved in B and
T cell responses. In general, most of these studies: (1) compared
two or more closely related cell types such as Th1 versus Th2
cells (Hamalainen et al., 2001; Yang et al., 2005), phenotypically
defined naive, effector, memory (Holmes et al., 2005; Kaech
et al., 2002; Lee et al., 2004;Willinger et al., 2005), and exhausted
versus functional effector and memory T cells (Wherry et al.,Immunity 32, February 26, 2010 ª2010 Elsevier Inc. 153
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Figure 1. Schematic of Enrichment Analysis
Enrichment analysis considers a rank-ordered profile of genes (e.g., those
genes differentially expressed in cells with phenotype A versus phenotype B)
and an independent set of genes from a database or separate experiment.
Each gene in the gene set is matched to a gene in the differentially expressed
list of genes in phenotype A versus B, and its position in the rank-ordered list
determined. The goal of enrichment analysis is to determine whether the
members of the gene set are primarily found at the top of the list, at the bottom
of the list, or randomly distributed throughout the list.
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Ehrhardt et al., 2008; Klein et al., 2003; Vinuesa et al., 2002),
(2) examined changes in gene expression in response to some
stimuli such as antigen or cytokines (Feske et al., 2001; Hess
et al., 2004; Liu et al., 2002), or (3) tracked longitudinal changes
in lymphocyte populations during an immune response (Kaech
et al., 2002). One common theme that emerged from many of
these studies is that they focused on detailed analysis of indi-
vidual genes identified through transcriptional profiling via differ-
ential expression and a fold-change cutoff. These gene-based
approaches have been very fruitful and have identified roles for
key molecules and pathways involved in memory B and T cell
differentiation and dysfunction such as CD127 (Kaech et al.,
2003), PD-1 (Barber et al., 2006), Blimp-1 (Kallies et al., 2009; Ru-
tishauser et al., 2009; Shin et al., 2009), Bcl-6 (Kim et al., 2004),
and many others. Thus, the gene-by-gene, knowledge-based
analysis of genomic transcriptional profiles data cannot be
underappreciated for its role as a discovery tool.
Limitations of Gene-by-Gene Microarray Analysis
Despite these insights, one drawback of this genome-scale data
is that even with relatively straightforward comparisons of two
different types of cells, the analysis can return lists of hundreds
or thousands of ‘‘potentially interesting’’ differentially expressed
genes. This scale of data poses significant problems for the
gene-by-gene analytical approach. Without an obvious unifying
biological theme, extracting meaning from these lists is usually
an ad hoc process that is dependent on a researcher’s area
of knowledge. In addition, by their nature such individual gen-
e-oriented ‘‘fold-change’’-based analyses ignore the vast
amount of data generated in whole-genome scale microarray
experiments.
The single-gene analytical approach also often tends to de-
emphasize the interrelatedness of genes involved in biological
processes. For example, a transcriptional network might involve
hundreds of genes. Biologically significant alterations in such
a pathway might involve marked changes in expression level in
only small number of genes in the network. However, focusing
on the one or two genes with dramatic changes in expression
level could miss the underlying biology reflected by coordinate,
but more subtle changes in multiple genes in the pathway.
This problem, of course, poses significant challenges for
the analysis of gene expression data. The magnitude of change
in expression level of a single gene is very easily calculated,
visualized, and communicated. Identifying changes distributed
across networks of genes is more difficult. Instead of viewing
lists of differentially expressed genes as independent events, a
great deal of effort is now focused on identifying coordinated
patterns of gene expression that are linked to specific biolog-
ical processes.
Integrating Gene Expression Signatures from Biological
Phenotypes: Detecting Enrichment of Gene Sets
Although traditional analytical approaches for gene expression
profiling data have focused on the handful of genes at the top
(or bottom) of the list of differentially expressed genes, several
groups have developed approaches to test for enrichment—
coordinated up- or downregulation—of biologically meaningful
sets of genes (see Figure 1). These advances depend on both154 Immunity 32, February 26, 2010 ª2010 Elsevier Inc.novel computational techniques and on the availability of cata-
logs of annotated sets of genes that can be used to interrogate
experimental data. Enrichment analysis has now become an
essential tool to integrate genomic data from different experi-
ments, different microarray platforms, and even different species
(Huang et al., 2009).
Many different computational approaches have been devel-
oped to test for enrichment of gene sets—each with their partic-
ular strengths and limitations (see Box 1; Huang et al., 2009;
Tilford and Siemers, 2009). However, all can be described in
the same conceptual terms. Enrichment analysis starts with a
profile of differentially expressed genes, such as those thatmight
be obtained by comparing, e.g., naive and effector CD8+ T cells
(Figure 1). By using an a priori defined gene set comprised of bio-
logically related genes, one can ask whether that set of genes, as
whole, tends to occur toward the top (or bottom) of the rank-
ordered set of all genes differentially expressed between naive
versus effector (or effector versus naive) T cell samples. Sets
of genes that are highly related to one cell type should be
distributed at the top of the rank-ordered list; gene sets that
are not related would be expected to be randomly distributed
throughout the list. Given any collection of gene expression
profiles in which genes can be rank-ordered by their differential
Approaches to Testing for Signature Enrichment
Many tools have been developed to test for enrichment of one or more sets of 
genes within a rank-ordered signature of genes from expression profiles. These
analytic approaches are used to ask whether a set of genes of interest tend to  
occur more toward the top (or bottom) of the rank-ordered list than would be 
expected by chance alone. These analytic approaches fall into one of two categories: 
threshold-based or non-threshold-based analysis. In the first, a gene signature is 
defined based on a threshold such as fold-increase or statistical significance (e.g., p 
value or FDR Q value). The portion of the rank-ordered list that is above the 
threshold is considered “upregulated.” A gene set of interest is then tested for 
overrepresentation within this signature of upregulated genes compared to the 
portion of gene set that is below the threshold. This analysis uses conventional 
statistical tests such as chi-square or Fisher's exact tests. Many gene sets can be 
tested sequentially, and the list of gene sets that are significantly overrepresented in 
the signature returned in order of their statistical significance. A drawback of this 
approach is that it requires the user to define a somewhat arbitrary cutoff in their 
differentially expressed gene list, and it ignores the contribution of the genes that 
fall below this cutoff. A second type of analysis has been developed that instead 
tests for relative enrichment of members of gene set of interest in the entire rank-
ordered list of genes. Gene sets that are unrelated to the cell types or treatment 
variable (i.e., class distinction) from which the signature was derived would be 
expected to be randomly distributed throughout the rank ordered list; in contrast, 
gene sets that are related would be expected to cluster at the top (or bottom) of the 
list of genes. The significance of this enrichment can be tested by comparing the 
true distribution of gene set members within the rank-ordered list with random 
permutations of the signature, for example, with a variant of the Kolmogorov-
Smirnov statistic (Lamb et al., 2003; Mootha et al., 2003; Subramanian et al., 2005).
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degree of enrichment of a given gene set at the top (highly corre-
lated) or bottom (anticorrelated) of the rank-ordered data set as
well as a statistical value for the confidence of the enrichment
compared to chance alone.
A key to the usefulness of gene set-based analysis is the defi-
nition of the gene sets of interest to be queried. In theory, enrich-
ment analysis can be done with any set of genes that is identified
a priori. However, in practice, enrichment analysis has become
more useful as catalogs of biologically meaningful gene sets
have become available (Bild and Febbo, 2005). Resources like
the Gene Ontology (Ashburner et al., 2000), KEGG (Ogata
et al., 1999), and TRANSFAC (Matys et al., 2003) databases
provide useful sets of gene annotation databases for biological
terms, pathways, and potential regulatory factors, respectively.
Mootha et al., for instance, showed that genes known to be
involved in oxidative phosphorylation were coordinately downre-
gulated in expression profiles from muscle in diabetic patients
compared to muscle samples from normal controls, underscor-
ing the strong relationship between oxidative phosphorylation
and non-insulin-dependent diabetes (Mootha et al., 2003).
What is more striking about this finding is that none of the indi-
vidual genes in the oxidative phosphorylation pathway were
strikingly downregulated in the microarray data set, with an
average of 20% difference in expression values for individual
genes in this gene set in diabetic versus nondiabetic muscle. In
other words, the relationship of genes in this pathway to the dia-
betic state may well have been overlooked without the greater
sensitivity afforded by enrichment analysis and the ability to
consider the genes in the pathway as a group compared to
a fold-change, gene-by-gene approach.
A second example of enrichment analysis is a recent study by
Pearce et al. who exploited the power of this approach to study
CD8+ T cell memory in mice with a T cell-specific deletion of the
gene TRAF6 (Pearce et al., 2003). These mice have normaleffector CD8+ T cell responses but severely compromised
CD8+ T cell memory, an observation that was not easily ex-
plained by the previously known roles of TRAF6. Analysis of
genes differentially expressed between TRAF6-deficient and
wild-type effector CD8+ T cells via enrichment analysis demon-
strated that sets of genes involved in fatty-acid metabolism
were underrepresented in TRAF6-deficient cells. These changes
in fatty acid oxidation (FAO) were then demonstrated experimen-
tally to be directly involved in memory CD8+ T cell differentiation
linking TRAF6, mTOR, and fatty acid metabolism to optimal
memory CD8+ T cell differentiation. Again, the FAO pathway
was not apparent without an enrichment analysis.
Testing for enrichment of GO terms has now become
a frequently used analytic approach for microarray data, and
one commonly used application, DAVID (http://david.abcc.
ncifcrf.gov), has been cited in more than 1000 publications (Den-
nis et al., 2003). However, although extremely valuable, enrich-
ment analysis with gene sets in databases like GO or KEGG
also has inherent limitations. First, genes in a given annotation
term (e.g., ‘‘oxidative phosphorylation’’ or ‘‘fatty acid metabo-
lism’’) are assigned based on knowledge, rather than direct
experimentation. The fraction of genes in GO or KEGG data-
bases that are incorrectly annotated is not known. Second,
even when genes are likely to belong to the sample biological
process, theymay not be coregulated at the transcriptional level.
Testing for coordinate upregulation of that pathway may there-
fore not be revealing even if the activity of the pathway is very
different between the two types of samples being compared:
the signal from the transcriptionally coregulated genes in the
pathway might be overshadowed by other members of the
gene set that are not coordinately regulated.
These limitations have led to increased interest in using exper-
imentally derived data sets for enrichment analysis. A growing
compendium of experimentally derived data sets is being
curated (and is available at Msigdb, http://www.broadinstitute.
org/gsea/msigdb/). Unlike GO or KEGG databases, these sets
of genes have been curated from analyses of previous gene
expression profiling experiments. The advantage of enrichment
analysis with gene sets defined through comparative expression
profiling is that these sets of genes have been defined biologi-
cally and require no researcher-dependent annotation. The
disadvantage is that the biological ‘‘meaning’’ of the set of genes
has to be inferred from the experiment that yielded the differen-
tially expressed genes. Nevertheless, testing for experimentally
derived gene sets can be a powerful tool to detect similarity
between phenotypes from different experiments based on
shared patterns of gene expression.
Integrating Signatures between Experiments
Several groups have applied integrated analysis of microarray
data from different experimental sources to extract biological
meaning from complex gene expression signatures and these
analyses depend on variants of enrichment analyses (Chtanova
et al., 2005; Luckey et al., 2006). For example, Luckey et al.
sought to determine whether memory T and B cells shared
similar patterns of gene expression to hematopoietic stem cells
(Luckey et al., 2006). There are obvious functional similarities
between HSCs and memory lymphocytes: both are capable of
self-renewal, and daughter cells derived from both HSCs andImmunity 32, February 26, 2010 ª2010 Elsevier Inc. 155
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one of several lineages depending on a range of development
cues. Supervised analysis of gene expression profiles from
memory CD8+ T cells was used to identify a set of genes
increased or decreased in memory T cells compared to their
non-self-renewing precursors (naive T cells and effector
T cells). These unique ‘‘memory’’ genes were found to be en-
riched in HSCs compared to lineage-committed hematopoietic
cells that lack the ability to self-renew. The implication of this
study is that memory lymphocytes reacquire the expression of
molecules characteristic of HSCs and may share common self-
renewal pathways. Importantly, however, the study also demon-
strated that integration of data from different sources could help
focus in on a specific biological property shared between the
data sets. It should be pointed out that such an analysis does
not necessarily mean that any individual gene in the gene set
identified by Luckey et al. was mechanistically causal for self-
renewal, because genes common to stem cells and memory
lymphocytes could be present as a consequence of the cell state
rather than a cause of the biological outcome. Investigating the
causal role of any gene in this gene set (or any other genes) for
the stem-cell-like self-renewal of memory lymphocytes requires
functional interrogation of candidate genes or sets of genes (see
below). However, this study demonstrates the value of using
enrichment analysis across different cell types and how enrich-
ment analysis represents a powerful tool to integrate sets of
genes that are surrogates for biological phenotypes.
Integrating Signatures between Species
The ability to integrate microarray data from diverse sources via
enrichment analysis is based on the fact that enrichment is de-
tected by the relative positions of a set of genes of interest in
a rank-ordered list of genes (see Box 1 and Figure 1). Because
the enrichment statistic is calculated based on evaluation of
gene rank and not absolute expression levels, comparison
across experiments, across platforms, or even across species
is possible (Subramanian et al., 2005).
For instance, we have used enrichment analysis to show that
the signature of genes upregulated in CD8+ T cells during
memory differentiation in the mouse model of LCMV infection
was highly significantly enriched in human memory-phenotype
CD8+ T cells (Haining et al., 2008b). Although phenotypic simi-
larity between human and mouse CD8+ T cells has been recog-
nized for a limited number of markers and parameters (Miller
et al., 2008), there are other aspects of mouse versus human
memory T cell biology that could be distinct (Mestas and
Hughes, 2004). The finding of a conserved memory T cell signa-
ture across species suggested that despite differences in some
individual genes, the fundamental transcriptional regulation of
memory development in humans and mice is highly conserved
at a genome-wide level. More surprisingly, the CD8+ T cell
memory signature was also enriched in CD4+ and B cell memory
cells in mice and humans, suggesting that memory differentia-
tion in different lymphocyte lineages may use common regula-
tory pathways even in different species.
Integrating Signatures between Genomic Platforms
Gene expression signatures have also been used to link different
types of genomic data. Working with stem cells, Lu et al. per-156 Immunity 32, February 26, 2010 ª2010 Elsevier Inc.turbed a key regulator of stem cell biology, Nanog, and then
analyzed the impact on the transcriptional, epigenetic, and pro-
teomic signatures of the stem cells as they differentiated
(Lu et al., 2009). By using unique computational approaches,
these authors were able to reconstruct the complex regulatory
effects of Nanog on stem cell biology. One interesting aspect
of this study is that, because the authors ‘‘multiplexed’’ four
genome-wide approaches (mRNAbymicroarrays, histonemodi-
fication by ChIP-chip, RNA Pol II gene active transcription by
ChIP-chip, and protein by proteomics), signatures were gener-
ated for sets of genes that were concordant or discordant across
different layers of biological regulation. In other words, signa-
tures were derived for genes and pathways that were regulated
transcriptionally, epigenetically, posttranscriptionally, and post-
translationally resulting from changes in Nanog expression. Such
combinatorial application of multiple types of genome-scale
data has also been proposed in the transplant setting (Sarwal,
2009) and is important for genome-wide ChIP-chip or ChIP-
seq studies where genome-wide mRNA profiles are necessary
to properly interpret epigenetic regulation of gene expression
(Araki et al., 2009; Wang et al., 2009).
Signatures as Tools for Drug Discovery
The idea of using a signature of genes as transportable pheno-
type that can be assayed in a variety of contexts is not new to
immunologists. For example, combinations of markers charac-
teristic of activated lymphocytes—such as CD25 and CD69—
can be assayed in CD4+ T cells just as easily as they can in
CD8+ T cells, and this signature can be readily used to determine
whether a set of experimental conditions activate T lympho-
cytes. The ability to use complex gene expression signatures
that are representative of subtly different phenotypes now
means that a broader range of cell phenotypes can be assayed
across experiments. In this section we will review how this
concept has been applied to detecting and deconstructing
gene expression signatures elicited by specific signaling path-
ways and as a tool for drug discovery. In most instances, these
emerging applications have not yet been broadly applied to
questions about immunological memory or vaccines. However,
many problems in adaptive immunity could be readily tackled
with similar approaches.
In cancer biology, identifying which oncogenes are active in a
particular tumor type or cell line has important clinical implica-
tions and can help shape the selection of therapies for a given
tumor. However, the increased activity of an oncogene is not
always evident from increased expression of the oncogene itself.
Analogous situations exist in inflammatory disease settings and
during persisting infections where relevant therapeutic targets
might not always be apparent. For tumor cells, several groups
have therefore asked whether gene expression signatures could
be used as surrogates for the activity of the oncogene pathway.
For example, overexpression of the oncogenesCyclinD1, K-Ras,
or Myc in cell lines is associated with distinct ‘‘pathway signa-
tures’’ that can be viewed as transcriptional surrogates for the
oncogenic state (Bild et al., 2006; Chang et al., 2009; Lamb
et al., 2003; Sweet-Cordero et al., 2005). These pathway signa-
tures have proved useful in two settings. First, as tools for bio-
logic discovery, they can be used to identify coregulated genes
some, or many of which, might be directly involved in conferring
Immunity
Perspectivemalignant potential (Lamb et al., 2003). These kinds of studies
could reveal new potential drug targets and mechanisms of
oncogenic pathways. Second, because they represent surro-
gates for activity of the oncogene, these signatures can be
used to query gene expression profiles from other cell types
for evidence of activity of that oncogene through enrichment
analysis. For instance, increased expression of the gene expres-
sion signature defined by overexpression of cyclin D1 can iden-
tify tumors with high levels of activation of this pathway (Lamb
et al., 2003). Signatures of oncogene activation can also help
match the right therapeutic compound to the right tumor (Bild
et al., 2006). Thus, even though the pathway signatures were
initially generated in laboratory-defined experimental settings,
the resulting signatures of gene expression are sufficiently
robust that they can be assayed in completely different cellular
contexts.
Integrating transcriptional signatures has been successfully
used as a discovery tool in the field of chemical genomics.
Several groups have created large compendia of gene
expression profiles of yeast cells (di Bernardo et al., 2005;
Hughes et al., 2000) or mammalian cells perturbed with drug
collections or by defined genetic manipulations (Lamb et al.,
2006). Similarities between transcriptional signatures induced
by disparate experimental manipulations have established
connections between the effects of small molecules and the
functions of individual genes and pathways on which they act.
For instance, Hughes et al. generated a collection of gene
expression signatures from 276 deletion mutants, 11 conditional
alleles, and wild-type yeast treated with 13 small molecules
(Hughes et al., 2000). Matching signatures from genetic and
chemical perturbations identified both the targets of small
molecules and the function of less-studied genes. Subsequently,
Lamb et al., by using mammalian cell lines, created a com-
pendium of more than 500 gene expression data sets from cell
lines treated with 164 different chemical compounds at dif-
ferent concentrations and for different durations (Lamb et al.,
2006). The resulting library of signatures was used to identify
previously unforeseen connections between glucocorticoid
resistance in acute leukemia and the effects of rapamycin (Wei
et al., 2006).
Similarly, gene expression signatures that represent desirable
phenotypes can serve as the endpoints for high-throughput
small molecule screens. This is particularly important when bio-
logical states lack easily screened phenotypes or defined protein
targets such as T cell memory. In this setting, a signature that
faithfully reflects a phenotype can provide a read-out of a chem-
ical or genetic high-throughput screen. This approach, termed
gene expression-based high-throughput screening, has been
used by Stegmaier and colleagues to identify the drugs that
cause acute myeloid leukemia to differentiate and become less
malignant (Hahn et al., 2009; Stegmaier et al., 2004, 2005). These
studies identified Syk as a target of gefitinib defining both a novel
target for this EGFR inhibitor and the role of Syk in acute myelog-
enous leukemia (AML) pathogenesis (Hahn et al., 2009). Such
approaches can be readily applied to phenotypic signatures in
the immune system and could have substantial value in immuno-
logical screening of adjuvants or even chemical compounds that
could foster more effective memory B or T cell differentiation
(Haining et al., 2008a).Future Directions: What Is the Point of Generating
Signatures?
The last decade haswitnessed an unprecedented increase in the
volume of biological data generated. Immunologists now have
at their disposal a growing compendium of genomic data that
represent specific phenotypes in the immune system. As the
technologies to generate these data become increasingly
applied to a larger number of biological states, it becomes impor-
tant to consider what overarching goals genomic technologies
might enable.
Correlates of Immunity
Few immunologists would disagree that there are likely to be
important biological differences between immune responses
that confer protective immunity and those that do not. However,
true correlates of protective immunity have remained elusive, as
illustrated by our difficulties in generating broadly protective
vaccines against HIV, HCV, influenza virus, malaria, and myco-
bacterium tuberculosis. Thus, important classes of biological
response to vaccines and pathogens are likely to exist but
have yet to be identified because of the lack of systematic and
unbiased approaches to recognizing such classes. Defining
such correlates and understanding the underlying protective
mechanisms are, of course, linked to an understanding of innate
immune responses and B and T cell memory. In this context,
genomic approaches have the potential to identify not only
signatures that represent cellular phenotypes, but also signa-
tures that correlate with important clinical phenotypes such as
immunologic protection.
Promisingly, recent studies have demonstrated that signatures
of protective vaccines can be generated with genomic
approaches and that, in some cases, it is possible to detect these
signatures even in whole populations of peripheral blood mono-
nuclear cells (PBMC) rather than in purified antigen-specific B or
T cells (Gaucher et al., 2008; Querec et al., 2009). Querec et al.
studied the gene expression profiles of PBMC in recipients of
the YFV-17D vaccine against yellow fever virus, obtained 7 days
after vaccination (Querec et al., 2009). With computational
models, they identified a pattern of genes that correlated with
the magnitude of the subsequent YFV-specific CD8 T cell
response and a separate signature of genes that correlated
with antibody titer. These signatures were then validated in an
independent trial in which PBMC microarray data was available
at the same time point. The gene expression-based signatures
could predict high versus low responders in this independent
validation trial with 80%–90% accuracy. For YFV, antibody titer
is a surrogate of protection and this study demonstrates that
even a few days after vaccination, protective levels of antibody
can be predicted by genomic signatures. The YFV-17D vaccine
also induces a robust CD8 T cell response (Akondy et al., 2009;
Miller et al., 2008), and it will be interesting in the future to deter-
mine how the gene expression signatures of this YFV-17D-
induced CD8 T cell response compares to other vaccines and
protective T cell responses in animal models. Thus, the ability
to prospectively identify genomic correlates of vaccine immuno-
genicity in this study is an important proof-of-principle.
A gene expression signature-based approach was also
used successfully to distinguish between systemic lupus erythe-
matosis (SLE) patients with different degrees of disease activity.Immunity 32, February 26, 2010 ª2010 Elsevier Inc. 157
Table 1. Examples of Signature-Based Predictors of Clinical
Phenotype
Immunologic
Perturbation Clinical Phenotype Reference
Vaccination immune response to yellow
fever virus vaccination
Querec et al., 2009
Infection influenza A versus E. coli or
S. pneumoniae infection
Ramilo et al., 2007
Autoimmunity juvenile rheumatoid arthritis
versus infection; SLE disease
activity
Allantaz et al., 2007;
Chaussabel et al., 2008
Graft rejection tolerance versus chronic
rejection
Brouard et al., 2007
GVHD donor-dependent risk
of GVHD
Baron et al., 2007
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coregulated sets of genes—modules—the aggregate expres-
sion of which correlated closely with disease activity and fluctu-
ated with disease flares (Chaussabel et al., 2008). Although this
study used these signatures to classify disease activity rather
than predict the subsequent clinical outcome of patients, this
work along with that of Querec et al. has laid an important foun-
dation for using unbiased analysis of transcriptional profiles as
a tool to quantify an immunologic event in humans. The use of
genomic signatures as predictors of clinical disease or outcome
is also beginning to be applied in an increasing number of other
immunological settings (Table 1). A future challenge will be to use
these signatures and predictors to also understand the under-
lying biology.
Important caveats remain when considering genomic corre-
lates of immune responses. First, just as with gene expression
profiling in basic immunology research, gene expression-based
predictors tend to deliver a list of individual genes without any
clear indication of their mechanistic role. For instance, Querec
et al. found that the product of a gene from the signature that pre-
dicted CD8 T cell response to YFV-17D—EIF2AK4—showed an
increase in phosphyorylation in dendritic cells incubated with the
vaccine strain of yellow fever virus. However, it is not immedi-
ately apparent how EIF2AK4 and the stress-response pathway
to which it belongs might regulate CD8+ T cell immunity. Just
as it is unlikely that an individual gene will have as much predic-
tive power as a signature generated from genomic data, it is also
unlikely that a single molecule will explain all of the underlying
biology associated with a complex phenotype such as protective
immunity. A key goal in the future will be tomake biological sense
out of genomic signatures of immunological protection or more
favorable course of a disease such as SLE and to rationally
design vaccines and therapeutics based on the insights gained.
A second caveat is that even genome-wide expression
profiles of a single compartment (e.g., PBMC) or lineage (e.g.,
CD8+ T cells) may not provide a dense enough representation
of the immune response to be predictive. To understand the
underlyingmechanisms of immunememory, it may be necessary
to define the contribution of individual components of the
immune signature of protection. For example, for vaccines that
work almost exclusively by antibody (nearly all current vaccines),
is the genomic signature of the T cell component relevant for158 Immunity 32, February 26, 2010 ª2010 Elsevier Inc.vaccines that must include robust cellular responses? Addition-
ally, is there a common transcriptional profile of protective
immune responses to respiratory infections and is this signature
shared with that for pathogen control in other anatomic
sites? The development of experimental and computational
approaches to acquire and combine data from multiple sources
will determine how to effectively use genomic approaches in
vaccinology. However, it is clear that a single parameter (IFN-g
ELISPOT) or a limited number of parameters (multicolor flow
cytometry) may not be sufficient to identify protective vaccines
or mechanisms of protective immunity for many challenging
infections (e.g., HIV, HCV, malaria, TB) (Pulendran, 2009).
One potential first step to taking advantage of genomics in
studying immunological memory and vaccinology is to define
the ‘‘ground state’’ of the immune system. Such an approach
is being taken by Benoist and colleagues, who are compiling
a comprehensive portrait of transcriptional profiles of the mouse
immune system by cataloging the transcriptional signatures of all
immune cell types at different states of development, stages of
immune response, and tissue microenvironments (Heng et al.,
2008). This compendium of transcriptional signatures will be of
tremendous value to both mouse and human immunologists
and should provide an important reference for comparisons
when the system is perturbed by vaccination or other immuno-
logical interventions. A second valuable approach is to develop
signatures of immune responses to natural infection in humans
and appropriate animal models, both successful and unsuc-
cessful. This is not a trivial exercise, but has been done in several
settings (Heltzer et al., 2009) including recently a comparison of
the ‘‘successful’’ immune response to SIV in sooty mangabeys
compared to the unsuccessful responses in rhesus macaques
(Bosinger et al., 2009). Here, it is likely that it will be possible to
define not only signatures to be emulated, but also those that
should be avoided (e.g., failure to control HIV, an excessive
inflammatory response after influenza virus infection). In addi-
tion, these approaches should be able to define signatures,
possibly even individual pathways uniquely associated with
different kinds of infections.
Operating Instructions
A second reason for acquiring comprehensive sets of signatures
that represent distinct phenotypes is to help generate an ‘‘oper-
ating manual’’ for how cells work. For example, if common
genomic signatures of protective immunity and immunological
memory can be defined via gene expression signatures or other
genomic approaches, these represent highly selected subsets of
the genome associated with important phenotypes. Signatures
therefore provide enriched pools of candidate genes as a starting
point for functionally annotating the genome. However, connect-
ing the constituent individual parts of a signature and long-term
immunity still will require mechanistic investigation and active
experimentation. The development of genome-scale shRNA
and open reading frame libraries has now provided the tools to
scan the genome for genes associated with aspects of the cell
phenotype at high throughput (Boutros and Ahringer, 2008; La-
mesch et al., 2007). For example, Amit et al. used a combination
of pathway signatures and functional annotation of signature
genes to define the underlying regulatory network associated
with the TLR-mediated response to pathogen-derived products
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Perspectiveby dendritic cells (DCs) (Amit et al., 2009). The authors sought to
reconstruct transcriptional regulatory networks that converted
signaling through TLRs into defined functional responses in
DCs. To do so, they first defined pathway signatures elicited in
mouse DCs after TLR stimulation. From these signatures, candi-
date regulators of TLR-induced responses were identified. The
authors then developed a library of shRNAs to silence the
expression of the 125 candidate regulators and again analyzed
transcriptional changes in response to TLR stimulation in the
presence of shRNAs. Of the 125 candidates, 100 were associ-
ated with at least 4 target genes. Of these, 24 were ‘‘hub’’ regu-
lators that were predicted to regulate more than 25% of the
genes in the signature in the TLR-stimulation induced response,
and another 76 regulators each affected a smaller number of
genes. Integration of genetic perturbation of the potential regula-
tors with expression profiling allowed the attributes of a TLR
signaling network to be reconstructed and identified a large
number of regulators not previously associated with the TLR
responses, such as those involved in cell cycle or circadian
rhythm.
In addition, this study identified several positive and negative
regulatory loops such as shutting off initial IFNB1 induction after
LPS simulation by the polycomb complex subunit gene Cbx4, an
event that confines the specificity of the type 1 IFN response to
poly I:C stimulation (Amit et al., 2009). The authors also link the
data they generated to genome-wide single-nucleotide polymor-
phism (SNP) analysis by noting that several of the regulators they
identified are in linkage disequilibriumwith SNPs associated with
autoimmunity. Thus, by using a combination of signatures of
specific biological phenotypes (TLR stimulation) with systematic
perturbation of more than 100 potential regulators, the authors
defined multiple layers and types of regulation of TLR-induced
responses. A key feature of this study was the ability to function-
ally annotate the relevant set of genes. By manipulating the
expression of the >100 key genes and integrating the resulting
expression profiles, the authors were able to ascribe biological
function and causality to the individual components of their initial
signature of genes. Such approaches could have particular rele-
vance for defining optimal adjuvants for vaccines as well as for
immunotherapies.
However, substantial challenges exist to achieving the goal of
functional annotation of all genes expressed by immune cells.
The role of many genes is context dependent, so the choice of
cell type and system for interrogation must be carefully consid-
ered. It will also be important, especially for the immune system,
to consider in vivo models rather than solely the use of in vitro
approaches. However, the immune system is perhaps an ideal
biological system to which to apply functional annotation of
genomic signatures. Many relevant cell types are well defined
and highly accessible in disease states, and in vitro assays
and animal models reflecting important immunological events
are plentiful.
Conclusions
The ever-expanding tool kit of genomic applications and new
computational approaches should provide immunologists and
vaccinologists with the opportunity to redefine signatures of
immunological memory to pathogens. Traditionally, such signa-
tures of different types of memory B and T cells have beendefined with a handful of cell surface or intracellular proteins or
functional readouts and flow cytometry. Flow cytometry remains
the only method for assessing the differentiation state of
individual cells rather than sometimes heterogeneous popula-
tions of cells in the immune system. However, the ability to define
signatures of immune responses in memory B and T cells via
genome-scale approaches will enable increasingly comprehen-
sive pictures of cell lineage, differentiation state, and activation
status to emerge. These approaches could allow precise predic-
tors of immunity to be developed and point to the underlying
mechanisms of immunological memory.
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